Characteristics and impact of Long Covid: Findings from an online survey

Nida Ziauddeen, Deepti Gurdasani, Margaret E O'Hara, Claire Hastie, Paul Roderick, Guiqing Yao, Nisreen A Alwan, Nida Ziauddeen, Deepti Gurdasani, Margaret E O'Hara, Claire Hastie, Paul Roderick, Guiqing Yao, Nisreen A Alwan

Abstract

Background: Long Covid is a public health concern that needs defining, quantifying, and describing. We aimed to explore the initial and ongoing symptoms of Long Covid following SARS-CoV-2 infection and describe its impact on daily life.

Methods: We collected self-reported data through an online survey using convenience non-probability sampling. The survey enrolled adults who reported lab-confirmed (PCR or antibody) or suspected COVID-19 who were not hospitalised in the first two weeks of illness. This analysis was restricted to those with self-reported Long Covid. Univariate comparisons between those with and without confirmed COVID-19 infection were carried out and agglomerative hierarchical clustering was used to identify specific symptom clusters, and their demographic and functional correlates.

Results: We analysed data from 2550 participants with a median duration of illness of 7.6 months (interquartile range (IQR) 7.1-7.9). 26.5% reported lab-confirmation of infection. The mean age was 46.5 years (standard deviation 11 years) with 82.8% females and 79.9% of participants based in the UK. 89.5% described their health as good, very good or excellent before COVID-19. The most common initial symptoms that persisted were exhaustion, chest pressure/tightness, shortness of breath and headache. Cognitive dysfunction and palpitations became more prevalent later in the illness. Most participants described fluctuating (57.7%) or relapsing symptoms (17.6%). Physical activity, stress, and sleep disturbance commonly triggered symptoms. A third (32%) reported they were unable to live alone without any assistance at six weeks from start of illness. 16.9% reported being unable to work solely due to COVID-19 illness. 37.0% reported loss of income due to illness, and 64.4% said they were unable to perform usual activities/duties. Acute systems clustered broadly into two groups: a majority cluster (n = 2235, 88%) with cardiopulmonary predominant symptoms, and a minority cluster (n = 305, 12%) with multisystem symptoms. Similarly, ongoing symptoms broadly clustered in two groups; a majority cluster (n = 2243, 88.8%) exhibiting mainly cardiopulmonary, cognitive symptoms and exhaustion, and a minority cluster (n = 283, 11.2%) exhibiting more multisystem symptoms. Belonging to the more severe multisystem cluster was associated with more severe functional impact, lower income, younger age, being female, worse baseline health, and inadequate rest in the first two weeks of the illness, with no major differences in the cluster patterns when restricting analysis to the lab-confirmed subgroup.

Conclusion: This is an exploratory survey of Long Covid characteristics. Whilst this is a non-representative population sample, it highlights the heterogeneity of persistent symptoms, and the significant functional impact of prolonged illness following confirmed or suspected SARS-CoV-2 infection. To study prevalence, predictors and prognosis, research is needed in a representative population sample using standardised case definitions.

Conflict of interest statement

The authors have no potentially competing interests to declare.

Figures

Fig 1. Frequency of reported ongoing symptoms…
Fig 1. Frequency of reported ongoing symptoms in survey participants (n = 2526).
Fig 2. Reasons for change in work…
Fig 2. Reasons for change in work pattern in those reporting reduced work hours (n = 243), being unable to work (n = 478) or being made redundant/taking early retirement (n-47) (total n = 768).
Fig 3. Two clusters of ongoing symptoms…
Fig 3. Two clusters of ongoing symptoms and acute symptoms among these clusters.
Fig 4. Adjusted associations with developing multisystem…
Fig 4. Adjusted associations with developing multisystem ongoing symptom cluster (OSC) 2.

References

    1. Nabavi N. Long covid: How to define it and how to manage it. BMJ. 2020;370. doi: 10.1136/bmj.m3489
    1. Callard F, Perego E. How and why patients made Long Covid. Social Science & Medicine. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426
    1. Perego E, Callard F, Stras L, Melville-Jóhannesson B, Pope R, Alwan NA. Why the Patient-Made Term “Long Covid” is needed. Wellcome Open Res. 2020;5:224. doi: 10.12688/wellcomeopenres.16307.1
    1. Nehme M, Braillard O, Alcoba G, et al.. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Ann Intern Med. Published online December 8, 2020. doi: 10.7326/M20-5926
    1. Petersen MS, Kristiansen MF, Hanusson KD, et al.. Long COVID in the Faroe Islands—a longitudinal study among non-hospitalized patients. Clinical Infectious Diseases. 2020;(ciaa1792). doi: 10.1093/cid/ciaa1792
    1. Altmann D, Boyton R. Confronting the pathophysiology of long covid. The BMJ. Published December 9, 2020. Accessed March 10, 2021.
    1. Puntmann VO, Carerj ML, Wieters I, et al.. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. Published online July 27, 2020. doi: 10.1001/jamacardio.2020.3557
    1. Huang Y, Pinto MD, Borelli JL, et al.. COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic. medRxiv. Published online March 5, 2021:2021.03.03.21252086. doi: 10.1101/2021.03.03.21252086
    1. Dennis A, Wamil M, Alberts J, et al.. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391. doi: 10.1136/bmjopen-2020-048391
    1. Davis HE, Assaf GS, McCorkell L, et al.. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38. doi: 10.1016/j.eclinm.2021.101019
    1. del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19. JAMA. 2020;324(17):1723. doi: 10.1001/jama.2020.19719
    1. Ladds E, Rushforth A, Wieringa S, et al.. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Services Research. 2020;20(1):1144. doi: 10.1186/s12913-020-06001-y
    1. Kingstone T, Taylor AK, O’Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the “right” GP: a qualitative study of the experiences of people with long-COVID. BJGP Open. 2020;4(5). doi: 10.3399/bjgpopen20X101143
    1. Office for National Statistics. Technical Article: Updated Estimates of the Prevalence of Post-Acute Symptoms among People with Coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021.
    1. Coronavirus (COVID-19) Infection Survey, UK Statistical bulletins—Office for National Statistics. Accessed December 18, 2020.
    1. Bliddal S, Banasik K, Pedersen OB, et al.. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep. 2021;11(1):13153. doi: 10.1038/s41598-021-92045-x
    1. Carfì A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603–605. doi: 10.1001/jama.2020.12603
    1. Lu Y, Li X, Geng D, et al.. Cerebral Micro-Structural Changes in COVID-19 Patients–An MRI-based 3-month Follow-up Study. EClinicalMedicine. 2020;25. doi: 10.1016/j.eclinm.2020.100484
    1. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. European Respiratory Journal. Published online January 1, 2020. doi: 10.1183/13993003.03276-2020
    1. Bergamaschi L, Mescia F, Turner L, et al.. Early immune pathology and persistent dysregulation characterise severe COVID-19. medRxiv. Published online January 15, 2021:2021.01.11.20248765. doi: 10.1101/2021.01.11.20248765
    1. García-Abellán J, Padilla S, Fernández-González M, et al.. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. J Clin Immunol. 2021;41(7):1490–1501. doi: 10.1007/s10875-021-01083-7
    1. Michelen M, Manoharan L, Elkheir N, et al.. Characterising long-term covid-19: a rapid living systematic review. medRxiv. Published online December 9, 2020:2020.12.08.20246025. doi: 10.1101/2020.12.08.20246025
    1. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance | NICE. Accessed December 18, 2020.
    1. Alwan NA, Johnson L. Defining long COVID: Going back to the start. Med (N Y). 2021;2(5):501–504. doi: 10.1016/j.medj.2021.03.003
    1. Lacobucci G. Covid-19: Lack of capacity led to halting of community testing in March, admits deputy chief medical officer. BMJ. 2020;369:m1845. doi: 10.1136/bmj.m1845
    1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus. Archives of Neurology. 1989;46(10):1121–1123. doi: 10.1001/archneur.1989.00520460115022
    1. Klok FA, Boon GJ a. M, Barco S, et al.. The Post-COVID-19 Functional Status (PCFS) Scale: a tool to measure functional status over time after COVID-19. European Respiratory Journal. Published online January 1, 2020. doi: 10.1183/13993003.01494–2020
    1. Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the Fatigue Severity Scale in a Swiss Cohort. Sleep. 2008;31(11):1601–1607. doi: 10.1093/sleep/31.11.1601
    1. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. Accessed April 12, 2021.
    1. Updated estimates of the prevalence of long COVID symptoms—Office for National Statistics. Accessed February 16, 2021.
    1. Miller TE, Beltran WFG, Bard AZ, et al.. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. The FASEB Journal. 2020;34(10):13877–13884. doi: 10.1096/fj.202001700RR
    1. Ward H, Cooke GS, Atchison C, et al.. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. The Lancet Regional Health–Europe. 2021;4. doi: 10.1016/j.lanepe.2021.100098
    1. Hellewell J, Russell TW, Matthews R, et al.. Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections. BMC Medicine. 2021;19(1):106. doi: 10.1186/s12916-021-01982-x
    1. Alwan NA. A negative COVID-19 test does not mean recovery. Nature. 2020;584(7820):170–170. doi: 10.1038/d41586-020-02335-z
    1. Alwan NA. The teachings of Long COVID. Commun Med. 2021;1(1):1–3. doi: 10.1038/s43856-021-00016-0
    1. Alwan NA. The road to addressing Long Covid. Science. 2021;373(6554):491–493. doi: 10.1126/science.abg7113
    1. Energy Envelope and prevention: Dr David Strain interview . @ABrokenBattery. Published February 25, 2021. Accessed March 20, 2021.
    1. Goërtz YMJ, Herck MV, Delbressine JM, et al.. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Research. 2020;6(4). doi: 10.1183/23120541.00542-2020
    1. Vaes AW, Machado FVC, Meys R, et al.. Care Dependency in Non-Hospitalized Patients with COVID-19. Journal of Clinical Medicine. 2020;9(9):2946. doi: 10.3390/jcm9092946
    1. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Accessed October 15, 2021.

Source: PubMed

3
購読する